lucatumumab

mAbexperimental

Lucatumumab is a human monoclonal antibody against CD40 development of which was discontinued by Novartis in 2013 after it was investigated for the treatment of various types of cancer like multiple myeloma and follicular lymphoma. — Wikipedia

Clinical trial activity

4 trials · 2 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Apr 1, 2005 (NCT00108108)

Timeline

2000s

Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
Jan 1, 2005
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Tumor necrosis factor receptor superfamily member 5ANTAGONIST
CD40 antagonist
- Tumor necrosis factor receptor superfamily member 5 (CD40) ↗
Tumor necrosis factor receptor superfamily member 5INHIBITOR
CD40 inhibitor
- Tumor necrosis factor receptor superfamily member 5 (CD40) ↗

Chemistry & pharmacology

Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Multi-specific: No

Oral

Parenteral

Topical

Sources

WikipediaLucatumumab ↗
ChEMBLCHEMBL1743038 ↗

Also known as

chir-12.12
hcd122
hcd-122
lucatumumab

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT01275209	Phase 1	Feb 1, 2011	Novartis
NCT00670592	Phase 1/Phase 2 (Phase 2)	Mar 1, 2008	Novartis, Xoma
NCT00231166	Phase 2	Sep 1, 2005	Novartis
NCT00108108	Phase 1	Apr 1, 2005	Novartis, Xoma

Showing 4 of 4 trials

Page 1 / 1

Organizations

Research & Development (2)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Novartis	For profit	4	4	2	2005
Xoma	For profit	2	0	2	2005

2 organizations

Page 1 / 1